MPG.eBooks - Description: Atypical injectable antipsychotics for schizophrenia or bipolar disorder

Cover Image

Read Now

Atypical injectable antipsychotics for schizophrenia or bipolar disorder a review of clinical effectiveness and cost-effectiveness

The purpose of this report is to evaluate the clinical effectiveness and cost-effectiveness, for the use of atypical injectable antipsychotics for patients with schizophrenia or bipolar disorder

Bibliographic Details
Main Authors:	Narain, Tasha, Ford, Caitlyn (Author)
Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health January 3, 2019, 2019
Edition:	Version 1.0
Series:	CADTH rapid response report: summary with critical appraisal
Subjects:	Schizophrenia / Drug Therapy Canada Cost-benefit Analysis Treatment Outcome Antipsychotic Agents / Therapeutic Use Antipsychotic Agents / Economics Bipolar Disorder / Drug Therapy
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK541213
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The purpose of this report is to evaluate the clinical effectiveness and cost-effectiveness, for the use of atypical injectable antipsychotics for patients with schizophrenia or bipolar disorder
Physical Description:	1 PDF file (20 pages) illustration